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Hepatitis C virus (HCV) is a major global health issue and successful treatment has been
associated with a reduction of risk of all-cause mortality. Advancements have been made
in HCV treatment through the use of interferon-free regimens. Most trials have been con-
ducted in HCV genotype (GT) 1 and data for interferon-free regimens in GT4 patients are
limited. The aim of this study was to evaluate the safety and efficacy of sofosbuvir plus sime-
previr in a real-world cohort of HCV GT4 patients with advanced fibrosis.
Patients and Methods
Eighty-seven GT4 treatment-naïve or –Interferon (IFN) ribavirin (RBV) experienced patients
treated with sofosbuvir and simeprevir +/- ribavirin (RBV) were enrolled in this cohort study
(41% severe fibrosis, 59% cirrhosis).
Results
Patients were 51.7% male, 78.2% IFN/RBV treatment-experienced, and 37.9% received
RBV treatment. The overall sustained virologic response at least 12 weeks after treatment
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(SVR12) rate was 87.4% while patients treated with and without RBV had rates of 87.9%
and 87% (p = 0.593), respectively, and patients with advanced fibrosis (F3) and patients
with cirrhosis had SVR12 rates of 94.4% and 82.4% (p = 0.087), respectively. SVR12 rates
in treatment-naïve patients and in IFN/RBV -experienced patients were 78.9% and 89.7%
(p = 0.191), respectively. Treatment failure occurred most commonly in patients with cirrho-
sis and severe disease. The treatment was well tolerated and no patient died or discontin-
ued treatment due to adverse events.
Conclusions
Sofosbuvir in combination with simeprevir +/- ribavirin in GT 4 HCV patients with advanced
fibrosis achieved high SVR12 rates and was well tolerated. RBV did not appear to increase
the rate of SVR12.
Introduction
Hepatitis C virus (HCV) is a major global health issue affecting 170 million patients worldwide
[1]. Chronic infection leads to progressive liver fibrosis, end stage liver disease, or hepatocellular
carcinoma [2,3] and successful treatment resulting in a sustained virologic response (SVR) has
been associated with a reduction of risk of all-cause mortality in HCV patients [4,5]. Advance-
ments have recently been made in HCV treatment through the use of interferon-free regimens
that combine direct-acting antiviral agents (DAA), resulting in high efficacy rates and a better
safety profile than those of interferon (IFN)-based regimens [6–10]. Most trials have been con-
ducted in Western countries where HCV genotype (GT) 1 is prevalent. The phase 2 COSMOS
study showed that combined simeprevir and sofosbuvir was efficacious and well tolerated in
HCV GT1 infections [11]. Based on the results of this study, this treatment was recommended
for GT1 HCV patients by the European Association for the study of the Liver (EASL) [12] and
the American Association for the Study of the Liver (AASLD) [13]. The phase 3 OPTIMIST-1
study confirmed these results [14] and additional large, prospective cohort studies showed that
combination of simeprevir plus sofosbuvir was associated with high rates of SVR and low rates
of treatment discontinuation in real-world patients with HCV GT1 infection [15,16].
HCV GT 4 accounts for 20% of HCV infections worldwide [17] and is most prevalent in
the Middle East and sub-Saharan Africa. In Egypt, GT4 accounts for approximately 90% of
HCV infections [18] and its prevalence has increased in several European countries, which is
considered to be a consequence of immigration [19–21]. The high genetic variability of HCV
GT4 infection includes 17 confirmed subtypes, with subtype 4a predominately seen in Egypt,
while Saudi Arabia and parts of Europe have high rates of subtypes 4a, 4c, and 4d [22,23].
Sofosbuvir or simeprevir in combination with pegylated IFN and ribavirin (RBV) improved
SVR in GT4 patients [24–26]. However, efficacy and safety data regarding interferon-free regi-
mens in HCV GT4 patients are currently scarce. Treatment with sofosbuvir and simeprevir
was recommended in EASL clinical practice guidelines for HCV GT4 patients, but this recom-
mendation was mainly based on the extrapolation of results in GT1 patients, since data with
this combination in GT4 patients was limited [12]. In Belgium, sofosbuvir and simeprevir
have been available since January 2015 for GT1 and GT4 patients with advanced fibrosis
(F3-F4 METAVIR) for 12 weeks. The aim of this observational study was to evaluate the safety
and the efficacy of this treatment in a real-world Belgian cohort of HCV GT4 patients with
advanced fibrosis.
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GT4- treatment naïve or –IFN/RBV experienced patients from 15 referral centers in Belgium
treated with sofosbuvir and simeprevir +/- ribavirin were enrolled between January and Sep-
tember 2015 in this observational study. Reference centers allowed to prescribe DAAs were
included in the study. All patients had advanced fibrosis (F3-F4) as required by national reim-
bursement criteria. Degree of fibrosis was defined at the beginning of treatment by histology
or by combination of an elastography test and a biological fibrosis score with a maximum age
of laboratory values of 1 year. The cut-offs for F3-F4 chronic HCV fibrosis assessment for tran-
sient elastography were for Fibroscan1 (Echosens, Paris, France): F39.5 kPA and F412.5
kPA, and for shear wave elastography: F38.7 kPA and F410.4 kPA [27,28]. The cut-offs for
biological fibrosis score for Fibrotest (Biopredictive) were F3:0.59–0.72, F3-F4:0.73–0.74, F4
0.75, for APRI: F31, F41.6, for FIB-4: F32.1, F3-F43.25, and F43.85 [29]. History of
hepatic decompensation was defined by prior or current diagnosis of ascites, hepatic encepha-
lopathy, spontaneous bacterial peritonitis or variceal hemorrhage. The study was performed
after approval by the “comite´ d’e´thique hospitalo-faculaire Erasme-ULB”: written informed
consent was not required by the “comite´ d’e´thique hospitalo-faculaire Erasme-ULB” because it
was a retrospective, non-interventional study. Moreover, the majority of patients had sustained
virological response after the treatment and was not followed regularly thereafter.
Treatment
Sofosbuvir + simeprevir treatment was considered as standard of care treatment for participants
as recommended by Belgian and EASL guidelines [12,30].The use of ribavirin (RBV) was at the
discretion of the treating clinician. All but two patients received 12 weeks of treatment. The
other two received 24 weeks of treatment. Patients were treated with a single 400 milligram tab-
let of sofosbuvir and a single 150 milligram tablet of simeprevir both taken orally daily. Ribavi-
rin dosing was variable across patients but for the majority (24/33) of patients, ribavirin was
administered according to body weight (<75 kg, 1000 mg/day and75 kg, 1200 mg/day in 2
doses). Patients were followed up for at least 12 weeks after the end of treatment.
Study assessments
Data collection included demographic data, history of previous HCV treatment, laboratory
data including levels of serum alanine aminotransferase (ALT), aspartate aminotransferase
(AST), total bilirubin, albumin, creatinine, hemoglobin, platelet count, International Normal-
ized Ratio (INR), and HCV RNA. Severity of cirrhosis was assessed by Child-Pugh and MELD
scores. These different parameters were also assessed at week 4 (W4) and week 12 (W12) of
treatment when available.
Treatment efficacy was measured as sustained virologic response (SVR)12 defined as HCV
RNA level below level of quantification at least 12 weeks after the end of treatment (EOT). For
patients who did not achieve SVR12, the frequency of relapse, and non-response was reported.
The numbers of patient lost-to-follow-up was also reported.
Statistical analysis
The primary endpoint was SVR12. Other efficacy endpoints were virological response at W4
and HCV RNA at the end of treatment. The primary analysis was done in the intention-to-
treat (ITT) population including all patients who received at least one dose of treatment. An
additional analysis of the primary endpoint was performed that excluded patients who did not
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have SVR12 values due to missing data, or lost to follow-up. The demographic data were com-
pared between groups using Student’s t-test or the Mann-Whitney U test as appropriate. Categor-
ical variables were studied using the two-sided Chi-square test. A p value<0.05 was considered
statistically significant. Calculations were performed with SPSS 18.0 software (Chicago, IL, USA).
Results
Patient population
Eighty-seven patients with HCV GT 4 were included between January 2015 and September
2015. Thirty-six patients (41.4%) had severe fibrosis (F3) and 51 (58.6%) were patients with
cirrhosis. The study population included 46 (51.7%) male and 68 (78.2%) IFN/RBV-experi-
enced patients. The majority of patients were black Africans (58.6%). Median age was 61 (30–
81) years and 9 patients were HCV/HIV co-infected. Thirty-three (37.9%) patients received
ribavirin treatment, 12 (33%) of patients with advanced fibrosis and 21 (41.2%) of patients
with cirrhosis. In patients with cirrhosis, median MELD score and Child-Pugh score were 8
(6–19) (range) and 5 (5–9) (range), respectively, 43.7% patients had platelet counts below 100
000/mm, 28.2% had albumin<35g/L and 13 patients had a history of liver decompensation.
At baseline, the clinical and demographic characteristics of patients who received ribavirin
were similar to those who did not receive ribavirin, except for ALT levels which were higher in
patients treated with ribavirin. The majority of patients received 12 weeks of treatment. Demo-
graphic and baseline characteristics are shown in Table 1.
Efficacy
In an ITT analysis, SVR12 rate was 87.4% (76/87). Among the patients who failed to achieve
SVR12, 5 had post treatment relapse, 1 patient had lack of efficacy during treatment with
detectable HCV RNA but below lower limit of quantification (LLOQ) at the end of treatment
and a relapse after, 1 patient was lost to follow up during the treatment but had a positive HCV
viral load after the end of treatment (no compliance data is available for this patient) and 4
patients were lost to follow-up after completing treatment. SVR12 in patients treated with
and without RBV were 87.9% (29/33) and 87% (47/54) (p = 0.593), respectively, and among
patients with cirrhosis, SVR12 in patients treated with and without RBV were 81% (17/21) and
83.3%(25/30) (p = 0.555), respectively. SVR12 in patients with advanced fibrosis (F3) and in
patients with cirrhosis were 94.4% (34/36) and 82.4% (42/51) (p = 0.087), respectively. More-
over, SVR12 in treatment-naïve patients and in IFN/RBV-experienced patients were 78.9%
(15/19) and 89.7% (61/68) (p = 0.191), respectively. HCV RNA at the end of treatment was
undetectable in 69 patients (79.3%). HCV RNA was detectable but below LLOQ in 12 patients
and data were missing for 6. However, among the 12 patients with detectable HCV RNA but
below LLOQ at the EOT, 10 achieved SVR12 (1 failure of treatment and 1 lost to follow-up).
The number of patients with undetectable HCV RNA at the EOT was higher in patients treated
with RBV (93.9%) than in patients without RBV (70.4%) (p = 0.007) (Fig 1A). An additional
analysis that excluded patients who did not achieve SVR12 for reasons other than virologic
failure (missing SVR12 data for 4 patients lost to follow-up) demonstrated an SVR12 rate of
91.6% (76/83) (Fig 1B). The characteristics of patients who failed to achieve SVR12 are shown
in Table 2. All but one patient who failed to achieve SVR12 were patients with advanced cir-
rhosis with high MELD score or low platelet count or low albumin level. Only one patient was
not a patient with cirrhosis but this patient was lost to follow-up during the treatment and no
compliance data was available for this patient.
Finally, HCV RNA was measured at week 4 of treatment in 67 patients. HCV viral load was
undetected in 22 patients (32.8%), 14/28 (50%) in patients treated with RBV and 8/39 (20.5%)
Sofosbuvir and Simeprevir in HCV Genotype 4
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in patients without RBV (p = 0.012). There was no SVR12 rate difference between patients
with undetectable HCV RNA at W4 (20/22; 90.9%) and patients with positive HCV RNA at
W4 (42/45; 93.3%) (p = 0.534).
Safety and tolerability
During the treatment, SAE were observed in 3 patients. One patient was hospitalized for ane-
mia due to rectal blood loss resolved after transfusion and not related to the treatment, 1
patient was hospitalized for encephalopathy not considered to be related to the treatment and
1 patient developed hepatorenal syndrome possibly related to the treatment. No patient died
or discontinued treatment due to adverse events. Among patients treated with and without
ribavirin, 5/33 (15.2%) and 3/51 (5.9%) had hemoglobin<10g/dl (p = 0.132) during the treat-
ment and ribavirin dose was decreased in 3 of the 33 RBV-treated patients and stopped in 3
patients. The 6 patients who modified RBV dosage during treatment all had cirrhosis. The
median baseline haemoglobin level for the 6 patients who modified their ribavirin dosage was
13.5 [11.5–15.3] g/dL compared with 14.4 [11.5–17.7] g/dL for the 27 patients who had no
modifications to their ribavirin dosage during the study (p = 0.190) and the median baseline
Table 1. Characteristics of genotype 4 hepatitis C patients treated with simeprevir plus sofosbuvir with or without ribavirin.
Characteristic Overall (n = 87) SOF/SMV (n = 54) SOF/SMV/RBV (n = 33) p
Median age, years (range) 61 (30–81) 61.5 (30–81) 58 (40–76) 0.381
Male sex, n/N (%) 46/87(52.9) 26/54(48.1) 20/33(60.6) 0.182
IFN/RBV-experienced patients, n/N(%) 68/87(78.2) 39/54(72.2) 29/33(87.9) 0.071
F3, n/N(%) 36/87(41.4) 24/54(44.4) 12/33(36.4) 0.303
F4, n/N(%) 51/87(58.6) 30/54(55.6) 21/33(63.6)
Ethnicity, n/N(%) 0.621
Black African 51/87(58.7) 34/54(63) 17/33(51.6)
Caucasian 26/87(29.9) 15/54(27.8) 11/33(33.3)
Middle East 8/87(9.2) 4/54(7.4) 4/33(12.1)
Maghrebin 1/87(1.1) 1/54(1.8) 0/33(0)







Median ALT, IU /mL (range) 67 (12–505) 57 (12–327) 80 (24–505) 0.01
Median bilirubin, mg/mL (range) 0.7 (0.1–5.7) 0.7 (0.2–5) 0.8 (0.1–5.7) 0.389
Median INR 1.1 (0.9–2.2) 1.1 (0.9–2.2) 1.1 (1–1.6) 0.808
Median platelet count, 10/mm (range) 131 (23–320) 135.5 (23–320) 118 (30–276) 0.277
Albumin, g/L (range) 40 (24.5–49) 40 (28–49) 40 (24.5–47.1) 0.472
Ascites (cirrhosis), n/N(%) 2/47(4.3) 2/28 (7.1) 0/19 (0) 0.350
Encephalopathy (cirrhosis), n/N(%) 1/46 (2.2) 0/27(0) 1/19(5.3) 0.413
MELD(range) (patients with cirrhosis) 8 (6–19) 8 (6–19) 9 (7–16) 0.341
Child-Pugh(range) (patients with cirrhosis) 5 (5–9) 5 (5–9) 5 (5–8) 0.670
Treatment duration 0.141
12W, n/N(%) 85/87(97.7) 54/54(100) 31/33(93.9)
24W, n/N(%) 2/87(2.3) 0/54(0) 2/33(6.1)
doi:10.1371/journal.pone.0170933.t001
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RBV dosage was 900 [800–1200] mg in patients who modified RBV dosage and 1200 [400–
1200] mg in patients without modification of RBV dosage (p = 0.189).
Fig 1. Patients who achieved sustained virological response 12 weeks after the end of treatment (A) In the
intention to treat population according to ribavirin treatment, degree of fibrosis, and treatment history. (B) In a
sensitivity analysis that excluded patients in whom HCV viral load at the end of treatment or 12 weeks post
treatment were missing.
doi:10.1371/journal.pone.0170933.g001
Table 2. Characteristics of patients who failed to achieved SVR12.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Fibrosis F4 F4 F4 F4 F4 F4 F3
Ribavirin No Yes Yes Yes No No Yes
Treatment-experienced No Yes Yes Yes Yes Yes Yes
HIV co-infection No No No No No No No
Ethnicity Caucasian Black African Caucasian Caucasian Black African Black African Caucasian
Age 41 66 48 56 49 69 59
Gender Male Female Male Male Female Male Male
Baseline MELD score 19 15 13 13 11 9 Not applicable
Baseline Child-Pugh score 9 8 8 5 7 Not applicable
Platelet count, 10/mm 100 50 30 42 35 61 Not reported
Albumin, g/L 28 30 24 36 28 Not reported
Baseline HCV RNA Positive 4.87 6.1 6.36 6.96 6.39 log 6.44
W4 HCV RNA 31 Not detected 51 Not detected 383 Not reported
EOT HCV RNA Not detected Not detected Not detected Not detected Not detected Weakly positive Not reported
PTW12 HCV RNA 177932 5618 432140 213796 44530000 Positive 2404200
doi:10.1371/journal.pone.0170933.t002
Sofosbuvir and Simeprevir in HCV Genotype 4
PLOS ONE | DOI:10.1371/journal.pone.0170933 January 26, 2017 6 / 11
Discussion
In this Belgian real-world cohort of HCV GT4 patients with advanced fibrosis, we showed that
the combination of SOF + SMV achieved in ITT analysis an SVR12 rate of 87.4%, 87.9% for
patients treated with RBV and 87% for patients treated without RBV. After exclusion of
patients who did not achieve SVR12 for reasons other than virologic failure, we observed an
SVR rate of 91.6%. These results showed that the combination of SOF+SMV is efficacious in
HCV GT4 patients with advanced fibrosis and that the addition of RBV did not appear to
increase the rate of SVR12 although patients treated with RBV seemed to have a faster decrease
of their viral load with a higher rate of negative viral load at week 4 and at the EOT. Interest-
ingly, some patients had detectable HCV RNA but below LLOQ at the EOT but achieved
SVR12. We did not observe a significant difference in SVR12 between patients with severe
fibrosis F3 and patients with cirrhosis. This may be due to the small size of the cohort. How-
ever, all but one patient who failed to achieve SVR12 were patients with cirrhosis and advanced
disease. This observation is consistent with results observed previously in other studies [15].
After exclusion of patients who did not achieve SVR12 for reasons other than virologic failure,
we observed an SVR12 rate of 87.5% in patients with cirrhosis. This result is comparable to the
result of the OPTIMIST-2 study in GT1 patients with cirrhosis treated with SOF + SMV, who
achieved SVR12 of 83% [31] while decompensated patients were excluded in this study. One
patient with positive viral load after the end of treatment was a patient without cirrhosis but
this patient was lost to follow-up during the treatment and no compliance data was available.
Finally, SVR12 rate in IFN/RBV experienced patients and treatment naïve patients was not sig-
nificantly different. Treatment was well tolerated. No patient died or discontinued treatment
due to adverse events. Among patients treated with RBV, 18% of patients modified ribavirin
dosage. The median baseline hemoglobin levels and the median baseline RBV dosage did not
differ between patients who modified ribavirin dosage compared with those patients who did
not. However, RBV posology was decreased only in patients with cirrhosis.
Limited data are currently available to guide treatment in chronic HCV GT4 patients espe-
cially with advanced fibrosis. However it is important to develop optimal treatment strategies
for HCV GT4 patients because this genotype is highly endemic in non-Western parts of the
world and its prevalence has increased in several European countries [19–21] Moreover, in
real life, patients with advanced fibrosis have an urgent need of treatment and robust data are
lacking for this population. Several treatment regimens containing sofosbuvir or simeprevir
have been evaluated previously for GT4 HCV patients. The combination of SOF and RBV for
24 weeks in a cohort of Egyptian patients showed an SVR rate of 90% but this cohort included
few patients with cirrhosis and the SVR rate in patients with cirrhosis was lower (78%) [32].
Recently, a real life study including HCV GT4 patients with advanced fibrosis showed that
SOF/SMV+/- RBV combination for 12 weeks was an effective regimen with an overall SVR
rate of 92% [33].Other studies including a few patients with cirrhosis showed that sofosbuvir
with ledipasvir [34] had also high SVR rates in GT4 patients. A recent study evaluated the effi-
cacy of the SOF+ ledipasvir+ RBV combination in GT1 and GT4 patients with cirrhosis and
seemed to be promising but the number of GT4 patients was low[35]. Other studies have eval-
uated the efficacy of newer direct-acting antiviral therapies for treatment of HCV GT4 patients
including the combination of grazoprevir and elbasvir [36]. This treatment seemed to be effi-
cacious but the results in patients with cirrhosis seemed to be worse [37]. The combination
of sofosbuvir and velpatasvir provided high rates of SVR among patients infected with HCV
genotypes 1,2,4,5, and 6, including those with compensated cirrhosis [38] and decompensated
cirrhosis [39]. However, this study included few GT 4 patients. The AGATE-1 study evaluated
the efficacy of the combination of ombitasvir and paritaprevir/ritonavir with ribavirin in HCV
Sofosbuvir and Simeprevir in HCV Genotype 4
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GT4 patients with cirrhosis. This study showed that this regimen is very efficacious for GT4
patients with cirrhosis [40]. However, conversely to the SOF-SMV combination, RBV use is
obligatory. Moreover, this combination is not allowed in patients with decompensed cirrhosis.
Indeed, post-marketing surveillance identified several cirrhotic patients who developed
hepatic decompensation or liver failure while receiving this therapy [41].
Our study is subject to several limitations. First, ribavirin treatment was not given after ran-
domization but only at the discretion of the treating clinician and the number of patients with cir-
rhosis receiving RBV is probably too small to show a potential benefit of RBV treatment in this
population. It is thus difficult to make definitive conclusions concerning the role of ribavirin in
the efficacy of treatment in our cohort of patients. Moreover, we had no data about resistance
associated variants (RAV) which might influence the treatment response. Indeed, in the COSMOS
study, the viral relapse rate was mainly correlated with mutations that have previously been associ-
ated with simeprevir resistance [11]. However, the Q80K mutation has not been reported in GT4.
In conclusion, we showed in this real-world cohort of GT4 patients with severe fibrosis and
cirrhosis that the combination of SOF and SMV is efficacious and well tolerated and represents
a good therapeutic option in HCV GT4 patients with advanced fibrosis and compensated cir-
rhosis. In patients with decompensated cirrhosis, second-generation IFN-free combinations
would be better suited.
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